RAPT Therapeutics Shares Plunge Premarket on FDA Study Hold
By Colin Kellaher
Shares of RAPT Therapeutics plummeted more than 65% in premarket trading Tuesday after a serious adverse event prompted the U.S. Food and Drug Administration to place a clinical hold on a pair of the biopharmaceutical company's studies in inflammatory diseases.
RAPT said the hold involves a Phase 2b study of its zelnecirnon drug candidate in atopic dermatitis, where one patient suffered a serious adverse event of liver failure, as well as a Phase 2a study of zelnecirnon in asthma.
The South San Francisco, Calif., company said that while the cause of the adverse event isn't yet known, it has been characterized as potentially related to zelnecirnon.
Details of the serious adverse event weren't disclosed. According to the FDA's website, serious adverse events are those that can cause disability, are life-threatening, result in hospitalization or death, or are birth defects.
RAPT said it was verbally notified of the hold by the FDA, and that it expects to receive a formal clinical-hold letter from the agency.
RAPT said it is thoroughly investigating the case, adding that the patient involved has a complex medical history, including the use of an herbal supplement known to be associated with liver failure and a reported Covid-19 infection during the time of the event.
RAPT shares, which closed Friday at $25.97, were recently down more than 65% at $9 in premarket trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 20, 2024 08:57 ET (13:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software